DDInter252 DDInter1435
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Bupropion {u} (Compound) treats {v} (Disease) obesity
Bupropion {u} (Compound) binds {v} (Gene) CYP2C8
Bupropion {u} (Compound) upregulates {v} (Gene) GPER1
Bupropion {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Bupropion {u} (Compound) is included by {v} (Pharmacologic Class) Increased Norepinephrine Activity
Bupropion {u} (Compound) downregulates {v} (Gene) HDAC6
Bupropion {u} (Compound) causes {v} (Side Effect) Female sexual arousal disorder
Bupropion {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Bupropion {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Bupropion {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxazosin
Bupropion (Compound) treats obesity (Disease)
Bupropion (Compound) binds CYP2C8 (Gene)
Bupropion (Compound) upregulates GPER1 (Gene)
Bupropion (Compound) palliates attention deficit hyperactivity disorder (Disease)
Bupropion (Compound) is included by Increased Norepinephrine Activity (Pharmacologic Class)
Bupropion (Compound) downregulates HDAC6 (Gene)
Bupropion (Compound) causes Female sexual arousal disorder (Side Effect)
Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Bupropion may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Doxazosin